吉非替尼治疗非小细胞肺癌的疗效与EGFR基因突变的关系

目的探讨吉非替尼治疗晚期非小细胞肺癌(NSCLC)的疗效与表皮生长因子受体(EGFR)基因突变的关系。方法选择36例Ⅲb期或Ⅳ期经铂类治疗方案无效的NSCLC患者,根据有无EGFR基因突变分为有EGFR基因突变组(A组,11例)与无EGFR基因突变组(B组,25例),均予以吉非替尼治疗,分析其疗效与EGFR基因突变的关系。结果 A组吉非替尼治疗有效率优于B组(81.8%vs.16.0%)(P<0.05)。结论 EGFR基因突变的检测可作为吉非替尼治疗NSCLC疗效的一个预测指标。

Relationship between epidermal growth factor receptor gene mutation and the efficacy of gefitinib in the treatment of advanced nonsmall-cell lung cancer

Objective To investigate the relationship between epidermal growth factor receptor(EGFR) gene mutation and the efficacy of gefitinib in the treatment of advanced nonsmall-cell lung cancer(NSCLC).Methods NSCLC in IIIb or Ⅳ stage was treated with gefitinib in 36 patients,who were devided into group A with EGFR gene mutation(11 cases) and group B without EGFR gene mutation(25 cases).The relationship between EGFR gene mutation and the efficacy of gefitinib was analyzed.Results The efectiveness rate of gefitinib therapy was higher in group A than that in group B(81.8% vs.16.0%)(P<0.05).Conclusion The detection of EGFR gene mutation may be taken as predicting index for evaluating the efficacy of gefitinib in the treatment of advanced NSCLC.